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Highlights 
x This review confirms that the effect of PTH peptides, as osteoporosis 
therapies, on peripheral bone mineral density (BMD) is different to that 
at the spine and hip. 
x PTH peptide monotherapy has trends for peripheral BMD losses 
compared to antiresorptives. 
x PTH peptides combined with antiresorptives reduced peripheral BMD 
losses found with monotherapy. 
x The peripheral fracture efficacy between PTH peptide mono and 
combined therapy remains uncertain.  
x Novel technologies, including HrpQCT, should be utilised in the 
development of novel anabolic treatments to better characterise their 
effects on peripheral BMD. 
*Highlights (for review)
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Abstract 
Given current developments in anabolic therapy for bone, we wished to document the effects of the only 
currently available anabolic therapy, parathyroid hormone (PTH) peptides, on the peripheral skeleton of 
postmenopausal women.  
We undertook a systematic review of English articles using MEDLINE, Scopus and the Cochrane Controlled 
Trials Register (final update 28th March 2016). Additional studies were identified through searches of 
bibliographies. Studies included those comparing PTH peptides with placebo, with anti-osteoporotic 
treatments and in combination therapies. Participants had to be postmenopausal women and outcomes 
included areal or volumetric bone mineral density (BMD) and measurements of bone microarchitecture at 
peripheral sites, such as the forearm and tibia. Data were extracted independently and reviewed by EMcC 
and LMM. Data on study design were also collected for methodological risk of bias assessment.  
The heterogeneity between studies, regarding the drug dose and duration, and the site measured, 
prevented grouped meta-analysis. There were no significant differences in areal BMD between PTH 
peptides and placebo at peripheral skeletal sites at 12 months. A decrease in aBMD occurred with PTH(1-
34) (larger dose) and PTH(1-84) treatment at 18 months follow-up in comparison to the placebo arms. Anti-
resorptives seemed to attenuate losses of aBMD at peripheral sites when compared to PTH peptides 
monotherapy, likely mediated by lower cortical porosity. Finally, PTH peptides combined with 
bisphosphonates or denosumab attenuated peripheral BMD losses in comparison to PTH peptide 
monotherapy, with evidence of increased BMD at ultradistal peripheral sites when PTH(1-34) was 
combined with denosumab or hormone replacement therapy. 
This summary should act as a reference point for the comparison of new anabolic therapies, specifically in 
comparison to PTH(1-34). 
  
Keywords: Anabolics, PTH peptides, Postmenopausal, Osteoporosis, Bone density, Peripheral skeleton 
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1 Introduction 
The treatment of osteoporosis is changing. The potential of anti-resorptive therapies to reduce 
fracture risk appears to have peaked with the development of easily administered, potent agents 
such as zoledronic acid and denosumab. However, despite increased efficacy of these agents to 
reduce vertebral fracture by approximately 65-70% versus placebo compared to 40-50% reductions 
seen with oral bisphosphonates versus placebo, anti-resorptive treatments have shown a relatively 
disappointing smaller relative risk reduction for non-vertebral, non-hip fractures (12-32%) versus 
placebo, when compared to the vertebral fracture risk reduction [1]. Non-vertebral, non-hip 
fractures, which include predominantly peripheral sites at the upper and lower limbs, comprise a 
significant proportion of the burden of fractures, especially at younger ages [2, 3]. However, even in 
85+ year olds, they still comprise 40-50% of fractures [2, 3]. It is unclear whether such fractures are 
somehow beyond the reach of bone-targeted approaches, or at least anti-resorptive therapies, as 
they may relate more to fall risk and other neuromuscular risk factors. 
Anabolic therapies may offer improved outcomes in this regard, though the data are relatively 
limited and the mechanisms remain unclear. Currently, PTH peptides are the only licensed anabolic 
therapy, either in the form of teriparatide (1-34 peptide fragment) or intact PTH (1-84 peptide). Both 
therapies are associated with early increases in bone-formation markers followed by a later increase 
in resorption markers [4, 5]. Improvements in aBMD with PTH(1-34), and PTH(1-84) to a lesser 
extent, have been established at the lumbar spine and proximal femur [6, 7] and both have been 
reported to reduce vertebral fracture risk. However, the effect of PTH peptides on peripheral 
fracture risk have been mixed; when comparing PTH(1-34) to placebo, there were reported 
reductions in wrist fractures in the pivotal phase III trial [8], but reductions were not found in the 
more recent ACTIVE phase III trial [9]. Furthermore, in the phase III study with PTH(1-84) there was 
no significant effect on wrist, upper-limb and lower-limb (non-hip) fractures [10]. 
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Recently, the analogue of PTH-related peptide (PTHrP 1-34; Abaloparatide) has been reported to 
improve fracture risk at vertebral and non-vertebral sites [9], though the treatment has not yet been 
licensed. Additionally, two sclerostin-targeted antibody therapies, romosozumab and blosozumab, 
have been tested in phase 2 studies, with romosozumab currently undergoing evaluation in a large 
phase 3 clinical program. The impact of these approaches in the peripheral skeleton and on non-
vertebral fracture risk are awaited with interest and will necessitate comparison with the effects of 
PTH peptides. For this reason, we have undertaken a systematic review of the efficacy of PTH 
peptides at peripheral skeletal sites to address three questions, comprising: (1) what is the effect of 
PTH peptides compared to placebo treatment on peripheral skeleton BMD? (2) What is the effect of 
PTH peptides compared to anti-resorptive treatments on peripheral skeleton BMD? (3) What is the 
effect of PTH peptides combined with other treatments compared to comparator monotherapy on 
peripheral skeleton BMD? 
2 Methods 
Following the PRISMA statement guidelines [11], we used a systematic approach to accurately 
identify all Level 1 eligible research to answer the questions outlined above. 
2.1 Eligibility criteria 
A stringent flow was used to identify eligible studies (Supplemental information 1). We searched for 
randomized studies in which participants were post-menopausal women and the interventions 
included at least one of the PTH peptide treatments (PTH(1-34) or PTH(1-84)) with a minimum 6 
months of follow up on therapy and must have reported changes in BMD from baseline. Studies with 
either blinded or open treatment allocation were considered. Studies required a comparator, such 
as a placebo or an FDA-approved anti-resorptive treatment (including hormone replacement 
therapy, HRT). Quantitative outcome measures included areal BMD (aBMD) and/or volumetric BMD 
(vBMD) of peripheral skeletal sites (forearm, tibia, metacarpals or metatarsals). Studies were 
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5 
restricted to the English language. Conference abstracts and unpublished findings were eligible, 
subject to the availability of study characteristics and data for outcome and risk of bias assessment. 
2.2 Information sources 
The search strategy included searching electronic databases, hand-searching the bibliographies of 
eligible articles and systematic reviews, and manufacturers of FDA-approved PTH peptides were 
contacted for unpublished findings. A piloted, electronic search strategy (Supplemental information 
2) was undertaken in PubMed MEDLINE (all years), Scopus (all years) and the Cochrane Central
Register of Controlled Trials (all years). Weekly updates were concluded on the 28th March 2016. 
2.3 Study selection 
Figure 1 provides a flow from search completion to study inclusion. Duplicates were removed and 
then the title, abstract and, where appropriate, the respective full-texts underwent data extraction. 
2.4 Data collection process 
In an attempt to avoid selective reporting bias from studies not presenting raw data, 6 authors (7 
studies) were contacted by email for raw study data points. Four authors (5 studies) responded with 
two providing numerical data that had been presented previously in graphical format. To avoid 
double counting data across studies, full texts were reviewed for indications of whether the study 
was an extension or sub-study. This was completed through tracking citations, the name of studies 
or trials and author names. To provide further clarity, the types of patients included, treatment 
durations and doses, comparators and the study outcomes (e.g. bone sites measured) were 
reviewed and compared (Supplemental information 3). 
2.5 Assessment of risk of bias 
Both EMcC and LMM reviewed the risk of bias assessment in included studies. LMM initially 
reviewed the allocation sequence for randomization and its concealment from investigators, the 
blinding of patients and investigators, patients lost to follow up, early termination of trials and 
whether intention-to-treat analysis was undertaken. During data extraction it was identified that a 
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risk of bias may stem from the sample sizes for peripheral skeletal measurements, due to lower 
numbers of patients used for these analyses compared to lumbar spine or proximal femur BMD, 
which were typically primary outcomes for studies. 
2.6 Summary measures 
The review describes quantitative changes from individual studies, rather than in summative form 
(meta-analysis), due to heterogeneity in study durations, PTH peptide dose and sites of peripheral 
skeletal measurements. The primary outcome was the mean difference in BMD from baseline to 
study endpoints for each peripheral bone site between (1) PTH peptide and placebo treatments, (2) 
PTH peptide and comparator treatments and (3) PTH peptide combined with other treatments 
compared to the comparator monotherapy. 95% CI and effect sizes were calculated from the mean 
differences between groups. A significant difference was stated when the 95% CI excluded zero. 
3 Results 
From an original search output of 1668 articles (Figure 1), a total of 41 manuscripts were 
subjected to full-text review. 27 studies/reports were excluded for the following reasons: absence 
of an RCT design (n=6), being a sub-study or extension (n=7), mixed gender participation 
(n=3), no standardization of the comparator treatment (n=1), duration less than 6 months (n=2), no 
peripheral skeleton measurements made and/or reported (n=6) and studies only reported within 
conference abstracts without sufficient detail (n=2). 14 articles (from 13 studies) were included 
in the final review. Two articles from the DATA study were included as they separately 
presented aBMD [12] and vBMD data [13]. 
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Figure 1. Study identification, screening, eligibility and inclusion in the review. 
Abbreviations: + - combined with another treatment 
The study characteristics, including study outcome measures, are shown in Table 1. Baseline 
characteristics of the women who participated in the 14 included studies are detailed in 
supplemental information 4. The previous use of osteoporosis therapy, garnered from inclusion and 
exclusion criteria varied between studies (Supplemental information 5); importantly, it was required 
that any pre-treated patients had been randomized to their respective treatment arms. All of the 
studies used concomitant daily calcium (500-1500mg daily) and/or vitamin D supplementation (400-
1200IU, or to maintain serum levels). Five of the 14 reports included placebo arms [8, 10, 14-16] and 
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10 had anti-resorptive treatment comparators (including 3 with HRT) [4, 5, 12, 13, 16-21]; please 
note that one study had both placebo and active comparator [16]. One study comparing two 
anabolics (PTH(1-34) to romosozumab) was not included in the analysis as this phase II trial assessed 
the efficacy of 5 different romosozumab doses and this treatment was not licensed at the time of 
this analysis [16]. DXA scanning produced aBMD data while measurements of vBMD were gathered 
using MRI [14] or HRpQCT [13]. Eleven studies presented BMD data to allow calculation of mean 
differences, 95% confidence intervals and effect sizes between treatment groups. 2 manuscripts 
reported mean changes without variation measures [18, 20] and a further 2 reported changes in 
graphical format only [15, 17]: these studies could not have quantitative comparisons of treatment 
groups. 
The degree of methodological risk of bias varied between studies (Supplemental information 6). All 
of the placebo-controlled trials were double-blind within at least some of the allocated treatment 
arms [8, 10, 14-16] but blinding was less common in studies comparing PTH peptides to other 
treatments, potentially due to difficulties in blinding injections compared to oral administration. Use 
of intention-to-treat analysis was reported in three placebo-controlled [10, 14, 15], four anti-
resorptive treatment-controlled comparisons [4, 12, 13, 17] and two trials combining PTH peptides 
with HRT [19, 20]. Several trials had a loss to follow up of over 15% including two studies 
investigating PTH(1-34) [8, 16] and one study investigating PTH(1-84) [10] that were placebo-
controlled, four PTH(1-34) peptide trials that were anti-resorptive treatment controlled [5, 12, 13, 
17] and when PTH peptides were combined with HRT [19, 21]. Several studies reported early
terminations due to reports of osteosarcoma in PTH peptide-treated rats [8, 17, 19, 21]. 
The data that the mean difference and 95% CI between the PTH peptide and comparator groups was 
calculated from has been compiled in the supplemental information (number 7 and 8). 
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3.1 PTH peptides compared to placebo 
Both PTH peptides were associated with trends to decrease aBMD within radial sites but, while 
these effects were often numerically greater, they were usually not significantly different from 
changes observed in the placebo groups (Table 2). The following between group differences in the 
percent change in aBMD from baseline (with 95% CI and effect size (d)) were found: significantly 
greater losses were reported at 18 months at predominantly cortical sites of measurement in the 
radial shaft with PTH(1-34) at a dose of 40 ʅg/day (-1.9 [-2.8, -1.0] d=0.48) and PTH(1-84) 100 ʅg/day 
(-3.46 [-4.66, -2.26] d=0.74) compared to placebo groups. There were no significant differences from 
placebo at the radius shaft with PTH(1-34) 20 ʅg/day or PTH(1-84) 100 ʅg once weekly over 12-18 
months of follow up. Interestingly, those studies that examined predominantly trabecular sites 
within the distal radius (ultradistal radius or distal radius) showed trends for increases with PTH, 
though this did not reach statistical significance with aBMD measurements (Table 2). However, using 
MRI to assess bone microarchitecture, there were significantly higher trabecular number (5.16 [1.41, 
8.90] d=1.02) and lower trabecular spacing (-8.98 [-16.11, -1.85] d=0.3) with the once-weekly PTH(1-
84) dose. Cortical thickness was measured, but not reported.
3.2 PTH peptides compared to anti-resorptive treatments 
At cortical sites within the radius, both PTH peptides showed significant decreases in aBMD 
compared to treatment with the anti-resorptive agents, alendronate or denosumab (Table 3). The 
following between group differences in the percent change in aBMD from baseline (with 95% CI and 
effect size (d)) were found: a higher PTH(1-34) dose  ?ŵĞĂŶ ? ? ? ?ʅŐ ?ĚĂǇ ?over 24 months led to a 
larger decrease in aBMD (-7.8 [-9.96, -5.64] d=2.1) compared to the 20 ʅg/day PTH(1-34) over 12 
months (-1.4 [-2.43, -0.37] d=0.24), in comparison to alendronate. PTH(1-84) at a dose of 100 Pg/
day 
appeared to have a numerically greater difference from alendronate (-2.67 [-3.69, -1.65] d=0.79) 
than PTH(1-34) 20 Pg/day. A similar reduction in aBMD during PTH(1-34) 20 Pg/day was observed 
when compared to denosumab alone over 24 months of treatment (-3.8 [-5.82, -1.78] d=0.97). 
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Tsai and colleagues [13] presented HRpQCT results as part of the DATA study at 24 months follow-
up. There were no differences in parameters measuring trabecular architecture between the PTH(1-
34) and denosumab treatment groups at either the radius or tibia, where trabecular vBMD was not
statistically different between the treatments (presented in graphs). In contrast, at both sites, 
cortical vBMD was lower in patients receiving PTH(1-34) compared to denosumab, albeit mean 
differences could only be calculated for the radius. Other data presented in graphs, such as cortical 
thickness and cortical tissue mineral density (TMD), followed a similar trend and there was higher 
cortical porosity with PTH(1-34), at both sites. 
3.3 PTH peptides combination therapy versus comparators 
Analyses showing a comparison of PTH peptides combined with a variety of anti-resorptives to the 
anti-resorptive alone are shown in Table 4. The following between group differences in the percent 
change in aBMD from baseline (with 95% CI and effect size (d)) were found: in studies combining 
PTH peptides with HRT there was significantly higher ultradistal radius aBMD with 40ug/day PTH(1-
34) and HRT compared to HRT monotherapy (2.36 [0.70, 4.02] d=0.57). However there was no
difference at the 1/3 distal radius site for HRT-PTH(1-34) combination (-0.72 [-2.16, 0.72] d=0.20) 
and for HRT-PTH(1-84) combination (-1.35 [-3.09, 0.39] d=0.32) when compared to HRT 
monotherapy. A lower aBMD was found in one study that combined 40ug/day PTH(1-34) with 
alendronate (vs. alendronate alone) after 24 months follow-up (-3.2 [-5.33, -1.07] d=0.87); the 
decrease was somewhat less than that induced by the use of PTH(1-34) alone at the same dose and 
duration (-7.8 [-9.96, -5.64] d=2.1). No difference was observed for PTH(1-84) in combination with 
alendronate compared to the latter alone over a 12 month period (-0.49 [-1.49, 0.51] d=0.18). 
Combination of PTH(1-34) with denosumab was not different to the effects of denosumab alone on 
aBMD at the 1/3 distal radius following 24 months treatment (0.1 [-1.55, 1.75] d=0.03). This was 
consistent with the distal radius for total vBMD, but this measurement increased with combined 
treatment at the distal tibia (1.60 [0.57, 2.63] d=0.96). Trabecular vBMD decreased with combined 
treatment at the radius, but changes were not different at the tibia, and there were no changes in 
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trabecular bone microarchitecture. Cortical vBMD and thickness were not different, plus no 
differences were reported in graphical representations of cortical TMD and porosity. There was no 
observed difference in distal radius stiffness (0.8 [-1.56, 3.16] d=0.18) and failure load (1.10 [-1.10, 
3.30] d=0.26) with combined treatment compared to denosumab, and there was no differences 
found at the distal tibia between these groups (in graph). 
4 DISCUSSION 
This summary review confirms that the administration of PTH peptides commonly leads to decreases 
in aBMD at sites of the peripheral skeleton that are predominantly cortical bone, such as the radius 
shaft and 1/3 distal radius. The relatively small changes in aBMD at these sites during treatment over 
a 12-18-month period are in marked contrast to the more substantial increases in aBMD at the 
lumbar spine and, to a lesser extent, the proximal femur [6, 7, 22]. The impact on peripheral aBMD is 
more marked when treatment with PTH peptides alone is compared to the effects of anti-resorptive 
treatments, either alone or in combination with PTH peptides. The decrease in aBMD, particularly at 
higher doses of PTH peptides (e.g. 40 ʅg/day vs. 20 ʅg/day), likely reflects hypomineralization of 
newly formed osteoid [23] and an increase in Haversian canal area [24] in cortical bone, contributing 
ƚŽĂŶĂƉƉĂƌĞŶƚ ?ĐĂƚĂďŽůŝĐ ?ĞĨĨĞĐƚŽŶŝŵĂŐŝŶŐŵĞĂƐƵƌĞŵĞŶƚƐ ?dŚĞŐƌĞĂƚĞƌĐŽŶƚƌĂƐƚǁŚĞŶĐŽŵƉĂred to 
anti-resorptives reflects the increased secondary mineralization and infilling of cortical porosity that 
occurs with the latter agents. The attenuation of markers of bone formation [3, 4, 11], as well as 
recent data in bone biopsies [25], support the attenuation of aBMD losses when PTH peptides are 
combined with anti-resorptives, compared to monotherapy [4, 5, 12, 13]. 
Indirect comparisons of PTH peptides across different placebo-controlled studies suggest that PTH(1-
84) has a trend for a greater loss of 1/3 distal radius aBMD than PTH(1-34) [8, 10]. Similar findings
are noted when compared to alendronate monotherapy [4, 16]. Local effects in radius aBMD 
compared to placebo may reflect the different wrist and upper-limb fractures risks between the 
PTH(1-34) and PTH(1-84) treatments [8, 10]. However, on assessing the upper-limb fragility fracture 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
12 
efficacy of PTH(1-34) at 20ʅŐ ?ĚĂǇin the two phase III trials, there was an approximate 55% 
reduction in the Fracture Prevention Trial [8], albeit with a small number of fractures, and a 5% 
reduction in ACTIVE [9] (Supporting information 9). When lower-limb and upper-limb fractures were 
combined in both trials, the peripheral fracture relative risk reduction [95% CI] decreased in both 
trials (Fracture Prevention Trial: 0.39 [0.14, 1.08]; ACTIVE: 0.78 [0.45, 1.37]). It is also worth noting 
that abaloparatide seemed to have better peripheral fracture efficacy compared to PTH(1-34) [9]. 
Given the more marked differences in peripheral BMD in head-to-head trials between PTH peptides 
and anti-resorptives, highlighted by large effects in aBMD [4, 5, 12, 16] and vBMD at peripheral sites 
[13], one can also ask whether differences are seen in the effects on peripheral skeleton fracture 
rates. Such assessments are limited by a paucity of direct head-to-head comparisons. Available 
studies, not limited to postmenopausal osteoporosis, have usually been insufficiently powered [17, 
26, 27] and have reported non-vertebral fracture rates (i.e. hip, rib, pelvis and peripheral skeletal 
fractures combined) [26, 27]. Despite apparent larger reductions in the pivotal teriparatide trial [8] 
than seen with antiresorptive agents, a recent systematic review suggests only modest differences 
on non-vertebral fractures, including hip fractures, between PTH(1-34), bisphosphonates and 
denosumab [28]. 
Based on reported differences in distal radius aBMD during PTH(1-34) alone compared to peptides 
combined with denosumab and HRT [12, 21], lower peripheral fracture risk might be anticipated. It 
remains uncertain whether even the greater increase in lumbar spine aBMD that is seen with 
densoumab combination therapy confers greater vertebral fracture protection [12], particularly 
when compared to the already highly effective PTH peptide monotherapy [8, 10]. Perhaps the 
greater argument for combination therapy arises from the effects on the peripheral skeleton, where 
the higher turnover in cortical bone during PTH peptide monotherapy may not provide optimal 
fracture reduction. Again, this hypothesis remains unproven due to the absence of sufficiently 
powered studies; intriguingly, the comparative fracture study with abaloparatide, a PTH peptide 
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analogue with apparently lesser effects on the stimulation of bone resorption, showed a greater 
reduction in upper limb fractures than that seen with PTH(1-34) therapy [9]. 
This review highlights moderate heterogeneity in the trial design and outcomes used to assess the 
peripheral skeletal effects of PTH peptides in RCTs. In order to better inform future trials, particularly 
those with novel anabolic therapies, a number of recommendations can be made that will assist 
future synthesis of the data: 
1. Treatment duration: comparisons should be assessed over the full treatment length to obtain
data that could be clinically relevant to peripheral fracture risk. 
2. Site selection: The 1/3 distal radius should be included as a comparator site for aBMD
assessment using DXA; this has been the most frequently reported site in trials to date and may 
indicate mechanistic differences of treatments on cortical bone. 
3. Utilization of HR-pQCT: HR-pQCT can quantify cortical and trabecular compartments and may
shed more light on peripheral adaptations with different treatments [13, 29, 30] and should be 
undertaken in at least a subset of study subjects. The technique can provide information on 
apparent bone strength and stiffness through finite element modeling, and measure adaptations 
of the endocortical transitional zone and regional cortical porosity [31, 32]. 
This review has a number of limitations to consider. For example, the analysis has been limited to 
women with postmenopausal osteoporosis whereas trials have also been undertaken in men with 
osteoporosis [33, 34] and with glucocorticoid-induced osteoporosis [35]; importantly, where results 
on the peripheral skeleton aBMD were reported, trials have found a similar trend to those reported 
in our review [33-35]. Secondly, other factors not included in the analysis might have influenced the 
differences found between different treatments. For instance, poor adherence to the treatments 
ŵĂǇ ƵŶĚĞƌĞƐƚŝŵĂƚĞ ĞĨĨĞĐƚƐ ďĞƚǁĞĞŶ ƚŚĞ ŐƌŽƵƉƐ ĂŶĚ ǀĂƌŝĂďŝůŝƚǇ ŝŶ ƚŚĞ ĐŽŚŽƌƚ ?Ɛ ĂŐĞ ?ethnicity, 
previous fracture incidence and other characteristics must also be recognized (Supplemental 
information 4). Prior therapy use could also have an impact; for example, prior HRT use was 
prevalent in PTH peptide and HRT combination studies. Third, we were unable to undertake a direct 
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comparison of PTH(1-34) and PTH(1-84), as there has not been an eligible head-to-head study.  
Nonetheless, the patterns of changes in bone at peripheral sites show a remarkable degree of 
consistency across the various studies and the conclusions drawn remain valid. Finally, while BMD 
has been used as a surrogate to determine differences between treatments, bone strength is 
however also dependent on bone morphology and bone material properties so that the impact on 
fracture risk remains to be better defined. 
In summary, the effects of PTH peptides at the peripheral skeleton are unlike responses at the 
lumbar spine and proximal femur, with reductions in aBMD found with increasing dose and duration 
of PTH peptides. Combination with anti-resorptives attenuate these reductions but the impact on 
fracture risk remains uncertain. In the absence of sufficiently powered studies, future inferences 
may have to be made from well-conducted imaging studies with appropriate finite element analysis. 
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Table 1.  Details of the 14 studies fulfilling the criteria for inclusion in this review. 
First author 
[ref] 
PTH Type Comparator Total follow up 
(months) 
Patient numbers Outcome: peripheral skeleton site 
PTH arm Comparator arm 
Black [4] 1-84
1-84 + ALN
ALN 12 104 (PTH) 
56 (PTH+ALN) 
55 aBMD: 1/3 DR 
Black [14] 1-84 PLA 12 25 24 aBMD: 1/3 DR, MR, UDR 
vBMD: DR 
Body [17] 1-34 ALN  ? ? ? 51 57 aBMD: 1/3 DR, UDR 
Cosman [18] 1-34 + RAL RAL 24§ 19 20 aBMD: Proximal radius* 
Cosman [15] 1-34 (x3
Tran. & Inj.)
PLA 6 Tran. 32 (20ʅg), 28 (30ʅg), 
32 (40ʅg); Inj. 32 (20ʅg) 
31 aBMD: Distal forearm* 
Finkelstein [5] 1-34
1-34 + ALN
ALN 30§§ 20 (PTH) 
20 (PTH+ALN) 
29 aBMD: Radius shaft* 
Fogelman [19] 1-84 + HRT HRT 18 43 58 aBMD: 1/3 DR 
Greenspan 
[10] 
1-84 PLA 18 117 119 aBMD: 1/3 DR 
Leder [12] 
Tsai [13] 
1-34
1-34 + DEN
DEN 24 28 (PTH) 
24 (PTH+DEN) 
31 aBMD: 1/3 DR 
vBMD: DR** and distal tibia** 
Lindsay [20] 1-34 + HRT HRT 36 13 17 aBMD: Proximal*, MF and UDF 
McClung [16] 1-34 ROMO (x5) & 
ALN & PLA 
12 42 48 (PLA) 
46 (ALN) 
aBMD: 1/3 DR 
Neer [8] 1-34 (x2) PLA 18 152 (20ʅg) 
145 (40ʅg) 
154 aBMD: Radius shaft*, DR 
Ste-Marie [21] 1-34 + HRT HRT  ? ? ? 48a/49b 45a/48b aBMD: 1/3 DRa, UDRb 
The patient numbers for each arm were determined by those that had outcome measurements following completion of the study treatment. This that 
did not complete the treatment has been removed.  
Total follow up: § PTH prescribed from months 0-12. §§ PTH prescribed from months 6- ? ? ? ? Median endpoint at 13.8 months. 
Outcome: * cortical bone site. ** sites used with standard patient evaluation protocols for HR-pQCT. 
Abbreviations: Inj.  ? Injection, Tran.  ? Transdermal, ALN  ? Alendronate, DEN  ? Denosumab, HRT  ? Hormone replacement therapy, PLA  ? Placebo, RAL  ? 
Raloxifene, ROMO  ? Romosozumab, DR  ? Distal radius, MR  ? Mid-distal radius, MF  ? Mid-distal forearm, UDR  ? ultradistal radius, UDF  ? Ultradistal 
forearm  
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Table 2. Mean difference [95% CI] between the PTH peptide treatment arm and placebo treatment arm for percentage 
change in areal BMD and volumetric measurements from baseline to study endpoint. 
Study PTH 
peptide 
PTH dose 
(ʅg/day) 
Duration 
(months) 
Outcome Mean % difference 
[95% CI] 
Effect 
size 
Device Measurement Bone site 
McClung [16] 1-34 20 12 DXA aBMD 1/3 DR -0.8 [-2.18, 0.58] 0.24 
Neer [8] 1-34 20 18 DXA aBMD DR 1.50 [-0.24, 3.24] 0.19 
40 18 DR 0.1 [-1.79, 1.99] 0.01 
20 18 RS -0.8 [-1.65, 0.05] 0.21 
40 18 RS -1.9 [-2.8, -1.0]* 0.48 
Black [14] 1-84 100§ 12 DXA aBMD 1/3 DR -0.6 [-1.81, 0.61] 0.28 
M-R -0.75 [-1.73, 0.23] 0.43 
UDR 0.31 [-1.50, 2.12] 0.1 
MRI BV/TV UDR 6.03 [-0.43, 12.50] 0.69 
Tb.N UDR 5.16 [1.41, 8.90] 1.02 
Tb.Sp UDR -8.98 [-16.11, -1.85]* 0.3 
Tb.Th UDR 1.21 [-3.58, 6.00] 0.19 
Ct.Th UDR NR - 
Greenspan 
[10] 
1-84 100 18 DXA BMD 1/3 DR -3.46 [-4.66, -2.26]* 0.74 
Mean difference was calculated by PTH peptide arm minus placebo arm. * indicates statistically significant differences.  
Abbreviations: DXA  ? Dual x-ray absorptiometry; MRI  ? Magnetic Resonance Imaging; aBMD  ? areal BMD; BV/TV  ? Bone 
volume fraction; Tb.N  ? Trabecular number; Tb.Sp  ? Trabecular spacing; Tb.Th  ? Trabecular thickness; Ct.Th  ? Cortical 
thickness; NR  ? Not reported; DR  ? Distal radius; M-R  ? Mid-radius; UDR  ? Ultradistal radius; RS  ? Radius shaft; 
Units: Dose - ʅg/day, § ʅg/week; Duration  ? months 
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Table 3. Mean difference [95% CI] between the PTH peptide treatment arm and comparator treatment arm for percentage change in 
areal and volumetric BMD from baseline to study endpoint. 
Study PTH peptide vs. 
Comparator 
PTH dose Duration 
(months) 
Outcome Mean % difference 
[95% CI] 
Effect 
size (ʅg/day) Device Measurement Bone Site 
McClung [16] 1-34 vs. ALN 20 12 DXA aBMD 1/3 DR -1.4 [-2.43, -0.37]* 0.24 
Finkelstein [5] 1-34 vs. ALN 28.5§ 24 DXA aBMD 1/3 DR -7.8 [-9.96, -5.64]* 2.1 
Black [4] 1-84 vs. ALN 100 12 DXA aBMD 1/3 DR -2.67 [-3.69, -1.65]* 0.79 
Leder [12] 
Tsai [13] 
1-34 vs. DEN 20 24 DXA aBMD 1/3 DR -3.8 [-5.82, -1.78]* 0.97 
HR-pQCT Tb.N DR 
DT 
-1.00 [-5.49, 3.49]
-2.00 [-7.21, 3.21]
0.11 
0.20 
Tb.Sp DR 
DT 
1.30 [-3.44, 6.04]
2.00 [-4.00, 8.00]
0.14 
0.17 
Tb.Th DR 
DT 
-0.80 [-3.76, 5.36]
1.30 [-4.14, 6.74]
0.09 
0.12 
Ct vBMD DR 
DT 
-3.80 [-5.30, -2.30]* 
NE 
1.32 
Mean difference was calculated by PTH peptide arm minus comparator arm. * indicates statistically significant differences.  
Dose: §  mean PTH dose; originally 40 ʅg/day 
Abbreviations: ALN  ? Alendronate; DEN - Denosumab; DXA  ? Dual x-ray absorptiometry; HR-pQCT  ? High-resolution peripheral 
quantitative computed tomography; aBMD  ? areal BMD; Tb.N  ? Trabecular number; Tb.Sp  ? Trabecular spacing; Tb.Th  ? Trabecular 
thickness; Ct.Th  ? Cortical thickness; DR  ? Distal radius; DT  ? Distal tibia; NA  ? Not estimable  
Units: Dose - ʅg/day; Duration  ? months 
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Table 4. Mean difference [95% CI] between the PTH peptide combined treatment arms and comparator treatment arms for percentage 
change in areal and volumetric BMD from baseline to study endpoint. 
Study PTH peptide + vs. 
Comparator 
PTH dose Duration 
(months) 
Outcome Mean difference 
[95% CI] 
Effect 
size (ʅg/day) Device Measurement Bone site 
Ste-Marie [21] 1-34+HRT vs. HRT 40 14 DXA aBMD 1/3 DR -0.72 [-2.16, 0.72] 0.20 
UDR 2.36 [0.70, 4.02]* 0.57 
Fogelman [19] 1-84+HRT vs. HRT 25 18 DXA aBMD 1/3 DR -1.35 [-3.09, 0.39] 0.32 
Finkelstein [5] 1-34+ALN vs. ALN 30.5§, 24 DXA aBMD 1/3 DR -3.2 [-5.33, -1.07]* 0.87 
Black [4] 1-84+ALN vs. ALN 100 12 DXA aBMD 1/3 DR -0.49 [-1.49, 0.51] 0.18 
Leder [12] & 
Tsai [13] 
1-34+DEN vs. DEN 20 24 DXA aBMD 1/3 DR 0.1 [-1.55, 1.75] 0.03 
HR-pQCT Total vBMD DR 
DT 
0.30 [-1.16, 1.76] 
1.60 [0.57, 2.63]* 
0.04 
0.96 
Tb vBMD DR 
DT 
-2.10 [-4.13, -0.07]* 
0.50 [-1.06, 2.06]
0.56 
0.17 
Tb.N DR 
DT 
 ? ? ? ? ?AL ? ? ? ? ? ? ? ? ? ?
 ? ? ? ? ?AL ? ? ? ? ? ? ? ? ? ?
0.22 
0.19 
Tb.Sp DR 
DT 
-2.20 [-6.32, 1.92]
-2.50 [-8.00, 3.00]
0.29 
0.24 
Tb.Th DR 
DT 
0.70 [-3.40, 4.80]
-2.20 [-7.20, 2.80]
0.09 
0.23 
Ct vBMD DR 
DT 
0.20 [-0.63, 1.03]
NE 
0.13 
- 
Ct.Th DR 
DT 
-0.40 [-2.78, 1.98]
2.10 [-0.24, 4.44]
0.09 
0.48 
Stiffness DR 
DT 
0.8 [-1.56, 3.16]
NE 
0.18 
- 
Failure Load DR 
DT 
1.10 [-1.10, 3.30] 
NE 
0.26 
-
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Mean difference was calculated by PTH peptide combined treatment arm minus comparator arm. * indicates statistically significant 
differences.  
Dose: §  mean PTH dose; originally 40 ʅg/day 
Abbreviations: ALN  ? Alendronate; DEN - Denosumab; HRT  ? Hormone replacement therapy; DXA  ? Dual x-ray absorptiometry; HR-pQCT 
 ?High-resolution peripheral quantitative computed tomography; aBMD  ? areal BMD; vBMD  ? Volumetric BMD; Tb vBMD  ? Trabecular
vBMD; Tb.N  ? Trabecular number; Tb.Sp  ? Trabecular spacing; Tb.Th  ? Trabecular thickness; Ct.Th  ? Cortical thickness; DR  ? Distal radius;
UDR  ? Ultradistal radius; DT  ? Distal tibia; NE  ? Not estimable
Units: Dose - ʅg/day; Duration  ? months
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Supplemental information 1. Flow for assessing study eligibility for the systematic review 
FACTORS ASSESSMENT 
TYPE OF STUDY
1. Randomised controlled trial
YES UNCLEAR NO 
Exclude 
PARTICIPANTS 
1. Women
2. Post menopausal
YES UNCLEAR NO 
Exclude 
INTERVENTIONS 
1. Parathyroid hormone (1-34 or 1-
84) alone vs. baseline or control
YES UNCLEAR NO 
Exclude 
CONTROL (Comparator) YES UNCLEAR NO 
Exclude 
OUTCOMES (Primary endpoint)
1. Peripheral skeleton  ? Upper and
lower extremities
2. Areal or volumetric bone mineral
density
YES UNCLEAR NO 
Exclude 
FINAL DECISION 
1 X No = Exclude
1 X Unclear = Unclear
*Manuscript
Click here to view linked References
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1. Exp postmenopause/
2. Postmenopaus$.tw.
3. Post-menopaus$.tw.
4. Post menopaus$.tw.
5. Or/ 1 - 4
6. exp osteoporosis/
7. osteoporos#s.tw.
8. osteoporotic.tw.
9. bone loss$.tw.
10. bone poros$.tw.
11. Or /6 - 10
12. 5 or 11
13. parathyroid hormone/ or teriparatide/
14. parathyroid hormone$ NOT hypoparathyroidism.tw.
15. parathyrin.tw.
16. parathormone.tw.
17. pth$.tw.
18. rhpth.tw.
19. teriparatide.tw.
20. Or/ 13 - 18
21. 12 and 19
22. exp clinical trial/
23. Clinical trial$.pt.
24. Controlled clinical trial$.pt.
25. Randomi#ed control.pt.
26. Placebos/ or Double-Blind Method/
27. Random$.tw.
28. Or/ 22  ? 27
29. 21 and 28
30. Limit 27 to (English language and humans)
31. >ŝŵŝƚ ? ?ƚŽ ?ĨĞŵĂůĞĂŶĚ “ĂůůĂĚƵůƚ ? ? ?ƉůƵƐǇĞĂƌƐ ? ? ?
Supplemental information 2. An example of the search strategy for MEDLINE (PubMed). 
Abbreviations: Exp  ? Explode; pt  ? publication type; pth  ? parathyroid hormone; rhpth  ? 
recombinant human parathyroid hormone; tw  ? Title/abstract; $ - different suffixes; # - 
alternative character 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Supplemental information 3. Data extraction form 
Reference 
Authors and year 
Title 
Journal, volume, page 
numbers 
Objective 
Stated study objective 
Study design 
Type of trial
Population 
Groups
Gender 
Total number; numbers 
per group 
Age (mean yrs)
Inclusion & Exclusion
Intervention 
Drug, administered 
amount 
Duration
Length of follow up 
Other notes
Compliance 
Drop outs 
(Reasons) 
Adverse events 
Control 
Control group or 
alternative intervention
Outcome 
Bone sites measured
How measurements 
were made
Other measures
Statistics 
Effect sizes and power
calculations 
Results Primary endpoint 
Statistically significant: 
Yes/No 
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28 
29 
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31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Secondary endpoint 
Statistically significant: 
Yes/No  
Comments 
For systematic review
Study quality 
Limitations 
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26 
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28 
29 
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Supplemental information 4. Patient characteristics of the 14 included randomised controlled trial reports assessing the effects of parathyroid hormone peptides on the 
peripheral skeleton in postmenopausal women. 
First author [ref] Age (years) BMI (kg/m2) T-score (SD) Baseline reported 
fracture (% or N) 
New fractures during 
trial (% or N) 
Treatment 
adherence 
Vitamin D 
status 
Black [4] 69.4 ± 7.3 vs. 
70.2 ± 6.8 vs. 
70.7 ± 6.8 
25.6 ± 4.6 vs. 27.1 ± 
5.6 vs. 25.1 ± 4.5 
FN -2.2 ± 0.7 47.9% vs. 50.8% vs. 
41.7% 
Approx. 3% in each 
group 
Full adherence: 
Injection = 75% 
Tablet = 81% 
NR 
Black [14] 57.6 ± 5.8 vs. 
58.9 ± 6.9 
26.9 ± 3.5 vs. 26.8 ± 
3.8 
LS -0.9 ± 1.2 vs. -1.1 ± 
1.0; TH -0.8 ± 0.6 vs. -
0.8 ± 0.7; FN -1.5 ± 0.4 
vs. -1.6 ± 0.4 
None NR Injections = >90% <15 ng/ml 
Body [17] 66 ± 8yrs vs. 65 ± 
9 
23.9 ± 4.5 vs. 24.4 ± 
3.5 
LS or FN < 2.5 NR Non-vertebral 4.1% 
vs. 13.7% 
Median 71% vs. 
67% 
NR 
Cosman [18] 67.2 ± 2.1 vs. 
66.7 ± 1.73 
25.1 ± 0.85 vs. 24.4 
± 0.83 
S AL ? ? ?A? ? ? ?ǀƐ ?AL ? ? ?A?
0.2; d,AL ? ? ?A? ? ? ?ǀƐ ?
AL2.0 ± 0.1  
Yes, with < AL2.0 SD or 
vertebral fracture 
alone 
NR All >80% Inclusion: 
>25 ng/dl
Cosman [15] 63.2 ± 6.8 vs. 
64.1 ± 7.5 vs. 
63.6 ± 5.8 vs. 
64.6 ± 7.3 vs. 
64.8 ± 7.1 
27.3 vs. 25.6 vs. 24.7 
vs. 25.5 vs. 26.6  
(Calculated from 
height and weight) 
LS -3.0 ± 0.6 vs. -3.0 ± 
0.5 vs. -3.2 ± 0.5 vs. -3.2 
± 0.7 vs. -3.2 ± 0.7; TH -
1.7 ± 0.6 vs. -1.5 ± 0.7 ± 
-1.7 ± 0.5 vs. -1.8 ± 0.7
vs. -1.6 ± 0.7
(N=) Vertebral, 8 vs. 6 
vs. 4 vs. 7 vs. 8 
NR Injection = >95% 
Patch = >85% 
<16 ng/dl or 
>80 ng/dl
Finkelstein [5] 65 ± 7 vs. 62 ± 7 
vs. 64 ± 6 
24.9 ± 3.6 vs. 25.4 ± 
5.1 vs. 25.6 ± 4.5  
PAS -2.1 ± 1.0 vs. -2.2 ± 
1.4 vs. -2.2 ± 1.1; FN -
2.2 ± 0.7 vs. -1.7 ± 0.8 
vs. -1.9 ± 0.8; TH -1.6 ± 
0.8 vs. 1.2 ± 0.8 vs. -1.5 
± 0.9; 1/3 DR -1.9 ±1.5 
vs. -1.3 ± 1.5 vs. -1.7 ± 
1.6 
NR NR At least 90%: 
TPTD (N) = 19 and 
17 
ALN (N) = 19 and 
27  
Inclusion: 
>15 ng/ml
Fogelman [19] 58.1 ± 6.2 vs. 24.3 ± 3.6 vs. 23.7 ± -2.30 ± 0.75 vs. -2.27 ± Vertebral: (N =) 3 vs. 3 >75% adherence: NR
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59.4 ± 6.8 3.7 0.91; TH = -1.50 ± 0.70 
vs. -1.55 ± 0.70; FN = -
1.89 ± 0.61 vs. -1.88 ± 
0.61 
None = 88.9% vs. 
87.8%; 1 = 8.9% vs. 
12.2%; >1 = 2.2% vs. 
0% 
96% vs. 97% 
Greenspan [10] 64.0 ± 7.4 vs. 
64.3 ± 7.8 
25.6 ± 4.34 vs. 25.7 
± 4.27 
LS -3.04 ± 0.78 vs. -2.97 
± 0.74; TH -1.89 ± 0.81 
vs. -1.84 ± 0.77; FN -
2.23 ± 0.71 vs. -2.17 ± 
0.71 
Any vertebral: 
17.5% vs. 16.4% 
New or worsened 
vertebral = 1.4% vs. 
3.4%; New vertebral 
w/out baseline 
fracture = 0.7% vs. 
2.1%; New vertebral 
w/ baseline fracture 
= 4.2% vs. 8.9%; 
Non-vertebral = 5.6% 
vs. 5.8% 
NR NM 
Leder [12] 
Tsai [13] 
65.5±7.9 vs. 
65.9±9.0 vs. 
66.3±8.3 
25.5±3.8 vs. 
25.4±4.9 vs. 
24.1±3.9 
>^ ?d, ?&EA?- ? ? ? ?A?-2.0 
ǁ ?ƌŝƐŬĨĂĐƚŽƌ ?A?-1.0 w/ 
fracture history. 
52% vs. 33% vs. 36% NR >85% TPTD:
Mono = 92%
Comb = 100%
DMAB = 100%
<20 ng/ml 
Lindsay [20] 59.5 ± 2.3 vs. 
64.2 ± 1.8 
24.0 ± 0.8 vs. 23.2 ± 
0.8 
< 2.5 SD (N=) 37 vs. 35, in 17 
vs. 17 subjects 
(N=) Vertebral 3 vs. 
10 
Minimum 
compliance 85% 
NR 
McClung [16] 66.8 ± 5.7 vs. 
67.0 ± 6.5 vs. 
67.1 ± 5.8 vs. 
66.7 ± 6.6 
NR LS -2.29; TH -1.53; FN -
1.93 
None after 50 yrs (N=) Romosozumab 
= 1 
NR <20 ng/ml 
Neer [8] 69 ± 7 & 71 ± 8 
vs. 70 ± 7 & 71 ± 
7 vs. 69 ± 7 & 69 
± 8 
26.8 ± 4.2 & 26.4 ± 
4.4 vs. 26.6 ± 4.3 & 
26.5 ± 4.1 vs. 26.7 ± 
4.7 & 26.5 ± 4.1 
LS = -2.6 SD Vertebral: 2.3 ± 1.8 & 
2.7 ± 1.7 vs. 2.3 ± 1.8 
& 2.3 ± 1.7 vs. 2.3 ± 
1.8 & 2.6 ± 1.8 
Vertebral (N=) 22 vs. 
19 vs. 64; Non-
vertebral (N=) 34 vs. 
32 vs. 53 
Average 79-83% NR 
Ste-Marie [21] 62.0±7.6 vs. 
61.1±7.4 
25.9±4.8 vs. 
25.8±4.7 
LS or TH <-1.0 NR NR 89% vs. 91% NR 
Age and BMI are presented as mean±SD. T-scores are indicated as mean, mean±SD, or as boundaries shown from inclusion criteria of studies. Prior or new fractures from
studies were presented as percentages (%) or as frequencies. Definition of treatment adherence was varied between studies and was 80% at minimum. Loss to follow up
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was given as a percentage or as a frequency per group studied. The vitamin D status was set as an exclusion criteria, unless stated otherwise. 
NR  ? Not reported; NM  ? Not measured; ng/dl  ? nanograms per deciliter; ng/dl  ? nanograms per milliliter; SD  ? Standard deviation; LS  ? Lumbar spine; PAS  ? Posterior-
anterior spine; S  ? Spine; TH  ? Total hip; FN  ? Femoral neck; T  ? Trochanter; DR  ? Distal radius 
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Supplemental information 5. Information available on the previous use of osteoporosis therapies in the study recruitment
First author [ref] Excluded participants based on previous osteoporosis therapy Reported statistics (number (%) unless stated 
otherwise) 
Black [4] Yes x Previous exposure to bisphosphonate was limited to no more than 12 months
ever, and no more than 4 weeks in the previous 12 months.
xAny previous alendronate use: 
x PTH(1-84) = 13 (10.9%)
x PTH(1-84)+ALN = 4 (6.8%)
x ALN = 10 (16.7%)
Black [14] Yes x Current use of bisphosphonates, estrogen, raloxifene, or calcitonin or previous
exposure to PTH.
x Previous exposure to bisphosphonate was limited to no more than 12 months
ever and no more than 4 weeks in the previous 2 years.
x No intravenous bisphosphonates.
xNone reported. 
Body [17] Yes x Taken medications or drugs known to affect bone or mineral metabolism in
the prior 2-24 months depending on the drug.
x This included androgens, anabolic steroids, bisphosphonates, calcitonin,
glucocorticoids, estrogens, fluoride, teriparatide, exogenous PTH or PTH
analogs.
xNone reported. 
Cosman [18] Yes* x The study only included patients that has previously taken raloxifene. xNot applicable: all had received raloxifene. 
Cosman [15] Yes x Prior PTH or PTH analog for a total duration of 3 months or at all within 6
months of randomization.
x Any use of fluoride or strontium.
x Calcitonin with 4 weeks, systemic estrogen or raloxifene within 3 months.
x Intravenous bisphosphonate within 2 years or more than two total doses.
x At least 6 months time off oral bisphosphonates if they had been taken for
more than 6 months; if oral bisphosphonates were used for 6 to 12 months
time off had to be at least 2 years; if previous oral bisphosphonate use
exceeded 12 months, then time off had to be at least 5 yr.
xNone reported. 
Finkelstein [5] Yes x Medications known to affect bone metabolism (referring to previous study in
men, Finkelstein et al., 2003 NEJM 349: 1216-1226).
xNone reported. 
Fogelman [19] Yes* x The study only recruited women receiving hormone replacement therapy. xPTH(1-84)+HRT: 
x Combination estrogen and progestin = 47
(52.2%)
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x Estrogens alone = 37 (41.1%)
HRT:
x Combination estrogen and progestin = 62
(68.9%)
x Estrogens alone = 30 (33.3%)
Greenspan [10] Yes x Excluded women if they had taken bisphosphonates for a total of more than
12 months or for more than 90 days in the 12 months before enrollment.
x Excluded women who had taken previous estrogen therapy within 4 weeks of
the screening visit.
x Excluded women who had received PTH (or a peptide fragment or analogue),
PTH-related protein, fluoride, or strontium.
xNo previous osteoporosis therapy in patients 
who completed the study: 
x PTH(1-84) = 565 (68.6%)
x Placebo = 635 (72.4%)
Leder [12] 
Tsai [13] 
Yes x Parenteral (intravenous) bisphosphonate; oral bisphosphonates within 6
months of enrolment.
x Teriparatide.
x Strontium ranelate.
x Estrogens, selective estrogen receptors modulators, or calcitonin within 3
months of enrolment.
xLeder 2014 (bisphosphonate use)** 
x PTH(1-34) = 13 (42%) with mean(SD) 27(20)
months since discontinuation
x PTH(1-34)+DMAB = 10 (33%) with mean(SD)
42(17) months since discontinuation.
x DMAB = 12 (36%) with mean(SD) 36 (23)
months since discontinuation
Lindsay [20] Yes* x Study inclusion required patients to take hormone replacement therapy for a
year leading up to enrolment.
xNone reported. 
McClung [16] Yes x Intravenous bisphosphonate or denosumab at any time.
x Fluoride within previous 24 months.
x Oral bisphosphonate, parathyroid hormone, or strontium within the previous
12 months.
x Calcitonin, selective estrogen receptor modulator, systemic oral or
transdermal estrogen or tibolone with the previous 3 months.
xNone reported. 
Neer [8] Yes x Drugs that alter bone metabolism within the previous 2 to 24 months,
depending on the drug.
xx PTH(1-34) 20 ʅg/day, % = 14-16%
x PTH(1-34) 40 ʅg/day, % = 13-14%
x Placebo, % = 14-15%
Ste-Marie [21] Yes/No x The study recruited patient previously treated with hormone replacement
therapy for 12 months preceding the study.
x There were no specific exclusion criteria for patients not taking hormone
replacement therapy for 12 months preceding the study.
xx Previous treated with HRT = 122: 48.8% were
randomized to the PTH(1-34)+HRT group.
x Not previously treated with HRT = 125: 50%
were randomized to the PTH(1-34)+HRT
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group. 
* Highlights that a specific inclusion criteria was included to counter any previous use of osteoporosis therapies.
** Leder [12] was used for the reported statistics as the DATA-HRpQCT study (Tsai [13]) lost patients to follow up. 
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Supplemental information 6. Assessment of methodological risk of bias from the 14 included study reports. 
First author [ref] Concealment of 
randomization 
RCT stopped 
early 
Patients 
blinded 
Healthcare providers 
blinded 
Outcome assessors 
blinded 
ITT 
analysis 
Loss to follow 
up >15% 
Black [4] NR No Yes Yes Unclear§ Yes No 
Black [14] NR No Yes Yes Unclear§ Yes No 
Body [17] NR Yes Yes Yes Unclear§ Yes Yes 
Cosman [18] NR No No No Yes NR No 
Cosman [15] Yes No Yes/No* Yes/No* Yes Yes No 
Finkelstein [5] Yes No No No Yes No Yes 
Fogelman [19] NR Yes Yes Yes Unclear§ Yes Yes 
Greenspan [10] Yes No Yes Yes Unclear§ Yes Yes 
Leder [12] 
Tsai [13] 
Yes No No No DXA = Yes 
HR-pQCT = NR 
Yes Yes 
Lindsay [20] Yes No No No NR Yes No = 15% 
McClung [16] Yes No No¶ No¶ NR NR Yes 
Neer [8] NR Yes Yes Unclear Unclear NR Yes 
Ste-Marie [21] No Yes Yes Yes Unclear§ NR Yes 
Abbreviations: NR  ? Not reported; RCT  ? Randomised controlled trial  
Studies that did not state clear outcomes related to the ŚĞĂĚŝŶŐƐǁĞƌĞĐůĂƐƐĞĚĂƐ  ?ŶŽƚƌĞƉŽƌƚĞĚ ? ?^ƚƵĚŝĞƐƚŚĂƚĚŝƐĐƵƐĞĚƚŚĞŽƵƚĐŽŵĞƐ ?ďƵƚǁĞƌĞƵŶĐůĞĂƌ ŝŶ
ƌĞƉŽƌƚŝŶŐǁĞƌĞĐůĂƐƐĞĚ ?hŶĐůĞĂƌ ? ?WĂƚŝĞŶƚĂŶĚŝŶǀĞƐƚŝŐĂƚŽƌďůŝŶĚŝŶŐŽƵƚĐŽŵĞƐĂƌĞĂƐƐŽĐŝĂƚĞĚǁŝƚŚWd,ƉĞƉƚŝĚĞƚƌĞĂƚŵĞŶƚŐƌŽƵƉƐ only. 
zĞƐ ?EŽ ? P ?zĞƐ ?ƚŽƚƌĂŶƐĚĞƌmal delivery of 1- ? ?Wd, ?ďƵƚ ?EŽ ?ƚŽ ?-34 PTH injections.  
§ The study was double-blinded, but was unclear if the outcome assessor was blinded or not blinded.
¶ Only blinded for Romosozumab and placebo groups 
>ŽƐƐƚŽĨŽůůŽǁƵƉAN ? ?A? P ?zĞƐ ?ŝĨŝŶĐƵƌƌĞĚŝŶat least one treatment group in the study. 
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Supplemental information 7. Areal BMD data from baseline to the study endpoint in the 14 study reports fulfilling the criteria for inclusion in this review
First author [ref] Peripheral skeleton site PTH type % change from baseline 
at study endpoint 
Comparator % change from baseline 
at study endpoint 
Mean SD Mean SD 
Black [4] 1/3 DR 1-84 -3.36 4.15 ALN -0.69 2.42 
1/3 DR 1-84+ALN -1.18 2.95 ALN -0.69 2.42 
Black [14] 1/3 DR 1-84 -1.12 2.36 PLA -0.52 1.95 
MR 1-84 -2.00 2.07 PLA -1.25 1.36 
UDR 1-84 -1.95 2.94 PLA -2.26 3.48 
Body [17] 1/3 DR 1-34 NR NR ALN NR NR 
UDR 1-34 NR NR ALN NR NR 
Cosman [18] Proximal radius 1-34+RAL -4.3 In graph PLA In graph In graph 
Cosman [15] Distal forearm 1-34 (x3 trans. & inj) All in graph All in graph PLA In graph In graph 
Finkelstein [5] 1/3 DR 1-34 -7.1 4.1 ALN 0.7 3.3 
1/3 DR 1-34+ALN -2.5 4.0 ALN 0.7 3.3 
Fogelman [19] 1/3 DR 1-34+HRT -0.448 0.778* HRT 0.903 0.430* 
Greenspan [10] 1/3 DR 1-84 -4.99 -5.89 to -4.08§ PLA -1.53 -2.32 to -0.74§
Leder [12] 1/3 DR 1-34 -1.7 4.6 DEN 2.1 3.1 
1/3 DR 1-34+DEN 2.2 3.1 DEN 2.1 3.1 
Lindsay [20] Proximal forearm 1-34+HRT 1 NR HRT NR NR 
MF 1-34+HRT NR NR HRT NR NR 
UDF 1-34+HRT NR NR HRT NR NR 
McClung [16] 1/3 DR 1-34 -1.7 -2.7 to -0.7§ PLA -0.9 -1.8 to 0.1§
1/3 DR 1-34 -1.7 -2.7 to -0.7§ ALN -0.3 -1.2 to 0.7§
Neer [8] Radius shaft 1-34 (20 ʅŐ ?ĚĂǇ ? -2.1 4.2 PLA -1.3 3.3 
Radius shaft 1-34 (40 ʅŐ ?ĚĂǇ ? -3.2 4.5 PLA -1.3 3.3 
Distal radius 1-34 (20 ʅŐ ?ĚĂǇ ? -0.1 7.2 PLA -1.6 8.3 
Distal radius 1-34 (40 ʅŐ ?ĚĂǇ ? -1.5 8.4 PLA -1.6 8.3 
Ste-Marie [21] 1/3 DR 1-34+HRT 0.64 0.46* HRT 1.36 0.57* 
UDR 1-34+HRT 4.2 0.66* HRT 1.84 0.53* 
* Standard error given; study analysis calculated the standard deviation. § 95% confidence interval given; study analysis calculated the standard deviation
Abbreviations: NR  ? Not reported, Inj.  ? Injection, Tran.  ? Transdermal, ALN  ? Alendronate, DEN  ? Denosumab, HRT  ? Hormone replacement therapy, PLA  ? Placebo,
RAL  ? Raloxifene, ROMO  ? Romosozumab, DR  ? Distal radius, MR  ? Mid-distal radius, MF  ? Mid-distal forearm, UDR  ? ultradistal radius, UDF  ? Ultradistal forearm
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Supplemental information 8. Volumetric BMD data from baseline to the study endpoint in the 14 study reports fulfilling the criteria for inclusion in 
this review 
First author [ref] Measurement Peripheral 
skeleton site 
PTH type % change from baseline 
at study endpoint 
 Comparator % change from baseline 
at study endpoint 
Mean SD  Mean SD 
Black [14] Bone volume 
fraction 
DR 1-84 2.34 9.29  PLA -3.69 8.07 
 Trabecular 
number 
DR 1-84 2.19 5.44  PLA -2.97 4.60 
 Trabecular 
spacing 
DR 1-84 -2.54 9.59  PLA 6.44 9.75 
 Trabecular 
thickness 
DR 1-84 0.26 6.72  PLA -0.95 6.19 
Tsai [13] Total vBMD DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
In graph 
3.3 
In graph 
4.2 
In graph 
3.2 
In graph 
2.1 
 
 
 
 
DEN 
DEN 
DEN 
DEN 
3.0 
3.0 
2.6 
2.6 
2.0 
2.0 
1.7 
1.7 
 Trabecular 
vBMD 
DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
In graph 
4.0 
In graph 
2.0 
In graph 
3.4 
In graph 
2.8 
 DEN 
DEN 
DEN 
DEN 
1.9 
1.9 
1.5 
1.5 
4.1 
4.1 
3.1 
3.1 
 Cortical vBMD DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
-3.1 
0.9 
-3.2 
1.2 
3.8 
1.6 
2.7 
1.6 
 DEN 
DEN 
DEN 
DEN 
0.7 
0.7 
In graph 
In graph 
1.5 
1.5 
In graph 
In graph 
 Cortical tissue 
mineral 
density 
DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
-3.1 
In graph 
-3.3 
0.7 
3.7 
In graph 
2.7 
1.2 
 DEN 
DEN 
DEN 
DEN 
In graph 
In graph 
In graph 
In graph 
In graph 
In graph 
In graph 
In graph 
 Trabecular 
number 
DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
-1.3 
1.4 
-3.9 
-0.1 
9.6 
7.8 
10 
8.8 
 DEN 
DEN 
DEN 
DEN 
-0.3 
-0.3 
-1.9 
-1.9 
7.8 
7.8 
10.4 
10.4 
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 Trabecular 
spacing 
DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
2.1 
-1.4 
5.1 
0.6 
10.3 
7.5 
11.5 
8.8 
 DEN 
DEN 
DEN 
DEN 
0.8 
0.8 
3.1 
3.1 
8 
8 
12 
12 
 Trabecular 
thickness 
DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
3.3 
3.2 
6 
2.5 
10.1 
7.9 
10.2 
7.8 
 DEN 
DEN 
DEN 
DEN 
2.5 
2.5 
4.7 
4.7 
7.4 
7.4 
11.1 
11.1 
 Cortical 
thickness 
DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
In graph 
4.7 
In graph 
8.1 
In graph 
5.3 
In graph 
4.3 
 DEN 
DEN 
DEN 
DEN 
5.1 
5.1 
6.0 
6.0 
3.1 
3.1 
4.5 
4.5 
 Cortical 
porosity 
DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
33.0 
In graph 
10.2 
In graph 
40.1 
In graph 
12.1 
In graph 
 
 
 
 
DEN 
DEN 
DEN 
DEN 
In graph 
In graph 
In graph 
In graph 
In graph 
In graph 
In graph 
In graph 
 Stiffness DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
In graph 
4.8 
In graph 
In graph 
In graph 
4.2 
In graph 
In graph 
 DEN 
DEN 
DEN 
DEN 
4.0 
4.0 
In graph 
In graph 
4.7 
4.7 
In graph 
In graph 
 Failure load DR 
 
DT 
 
1-34 
1-34+DEN 
1-34 
1-34+DEN 
In graph 
4.9 
In graph 
In graph 
In graph 
3.8 
In graph 
In graph 
 DEN 
DEN 
DEN 
DEN 
3.8 
3.8 
In graph 
In graph 
4.5 
4.5 
In graph 
In graph 
* Standard error given; study analysis calculated the standard deviation; § 95% confidence interval given; study analysis calculated the standard 
deviation 
Abbreviations: DEN  ? Denosumab, PLA  ? Placebo, DR  ? Distal radius, DT  ? Distal tibia 
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Supplemental information 9. Relative risk ratios for peripheral fractures between PTH peptides and placebo 
within upper-limb, lower-limb and all peripheral fractures combined. 
 
Table 9.1. Upper-limb fractures for PTH(1-34) compared to placebo 
First author [ref] PTH(1-34) dose PTH(1-34) Placebo Risk ratio (95% CI) 
Fractures Total Fractures Total 
Neer [8] 20 ʅŐ ?ĚĂǇ 4 541 9 544 0.45 [0.14, 1.44] 
 40 ʅŐ ?ĚĂǇ 5 552 9 544 0.55 [0.18, 1.62] 
Miller [9] 20 ʅŐ/day 19 818 20 821 0.95 [0.51, 1.77] 
Total  28 1911 38 1909 0.74 [0.45, 1.20] 
 
Table 9.2. Upper-limb fractures for PTH(1-84) compared to placebo 
First author [ref] PTH(1-84) Placebo Risk ratio (95% CI) 
Fractures Total Fractures Total 
Greenspan [10] 37 1286 27 1246 1.33 [0.81, 2.17] 
Total 37 1286 27 1246 1.33 [0.81, 2.17] 
 
Table 9.3. Lower-limb fractures for PTH(1-34) compared to placebo 
First author [ref] PTH(1-34) dose PTH(1-34) Placebo Risk ratio (95% CI) 
Fractures Total Fractures Total 
Neer [8] 20 ʅŐ ?ĚĂǇ 1 541 4 544 0.25 [0.03, 2.24] 
40 ʅŐ ?ĚĂǇ 4 552 4 544 0.99 [0.25, 3.92] 
Miller [9] 20 ʅŐ ?ĚĂǇ 2 818 7 821 0.29 [0.06, 1.38] 
Total  7 1911 15 1909 0.46 [0.19, 1.14] 
 
Table 9.4. Lower-limb fractures for PTH(1-84) compared to placebo 
First author [ref] PTH(1-84) Placebo Risk ratio (95% CI) 
Fractures Total Fractures Total 
Greenspan [10] 26 1286 28 1246 0.90 [0.53, 1.53] 
Total 26 1286 28 1246 0.90 [0.53, 1.53] 
 
Table 9.5. All peripheral fractures for PTH(1-34) compared to placebo 
First author [ref] PTH(1-34) dose PTH(1-34) Placebo Risk ratio (95% CI) 
Fractures Total Fractures Total 
Neer [8] 20 ʅŐ ?ĚĂǇ 5 541 13 544 0.39 [0.14, 1.08] 
40 ʅŐ ?ĚĂǇ 9 552 13 544 0.68 [0.29, 1.58] 
Miller [9] 20 ʅŐ ?ĚĂǇ 21 818 27 821 0.78 [0.45, 1.37] 
Total  35 1911 53 1909 0.66 [0.43, 1.01] 
 
Table 9.6. All peripheral fractures for PTH(1-84) compared to placebo 
First author [ref] PTH(1-84) Placebo Risk ratio (95% CI) 
Fractures Total Fractures Total 
Greenspan [10] 63 1286 55 1246 1.11 [0.78, 1.58] 
Total 63 1286 55 1246 1.11 [0.78, 1.58] 
 
Notes. All fracture data was obtained from published manuscripts: data for PTH(1-34) treatment compared to 
placebo excluded fractures from high trauma; data for PTH(1-84) treatment compared to placebo included both low 
trauma and high trauma fractures.  
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Neer [8]: reported wrist and humerus fractures separately, which we included in the upper-limb fracture 
calculations; reported ankle and foot fractures, which we included in the lower-ůŝŵď ĨƌĂĐƚƵƌĞĐĂůĐƵůĂƚŝŽŶƐ ?  ?KƚŚĞƌ ?
non-vertebral fractures were reported in the manuscript, but with no further detail into the individual fracture sites 
so were included in the calculations. 
Miller [9]: reported fingers, forearm, upper arm and wrist fractures separately, which we included in the upper-limb 
fracture calculations; reported ankle, foot, lower leg (not ankle) and upper leg (not hip) fractures separately, which 
we included in the lower-limb fracture calculations. 
Greenspan [10]: reported upper-limb and wrist fractures separately, which we included in the upper-limb fracture 
calculations; reported lower-limb fractures, which we included in the lower-limb fracture calculations. Data may 
include multiple fractures from one person. 
Analysis was completed in Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2012. 
